Investigation of ErbB2 immunity in human breast cancer employing recombinant expression sources in. immunoblot analysis revealed ErbB2-specific antibodies of the IgG isotype in sera of 14 of 71 cancer patients and 1 of 31 normal donors. Reactivity was confirmed on ErbB2-specific immunoprecipitates. Independent evidence of existing ErbB2 immunity was obtained after in vitro transformation of peripheral blood leukocytes from six positive patients. Furthermore, in vitro immortalization of B-lymphocytes unmasked existent ErbB2 immunity in 1 of 8 patients negative for ErbB2 serum antibodies. Determining shed ErbB2 extracellular domain as an indirect measure of tumor burden in ErbB2-positive malignancy, elevated serum levels were observed in 16 of 71 breast cancer and 1 of 31 normal donor sera Strikingly, existing ErbB2 immunity correlated significantly with elevated shed ErbB2 ectodomain among the patients analyzed. Incidence of both ErbB2 immunity and elevated ErbB2 extracellular domain increased with a progressed disease stage and was significantly associated with metastatic breast cancer. These observations implicate soluble ErbB2 amounts in vivo in the development of ErbB2 immunity in breast canter. They further project serum analysis of ErbB2 immunity and soluble ectodomain as potential markers of disease progression in ErbB2-positive malignancy.

ErbB2 immune response in breast cancer patients with soluble receptor ectodomain / Visco, Vincenzo; Roberto, Bei; Enrica, Moriconi; Gianni W., Kraus Mh; Raffaella, Muraro. - In: THE AMERICAN JOURNAL OF PATHOLOGY. - ISSN 0002-9440. - 156:4(2000), pp. 1417-1424. [10.1016/s0002-9440(10)65010-9]

ErbB2 immune response in breast cancer patients with soluble receptor ectodomain

VISCO, Vincenzo;
2000

Abstract

Investigation of ErbB2 immunity in human breast cancer employing recombinant expression sources in. immunoblot analysis revealed ErbB2-specific antibodies of the IgG isotype in sera of 14 of 71 cancer patients and 1 of 31 normal donors. Reactivity was confirmed on ErbB2-specific immunoprecipitates. Independent evidence of existing ErbB2 immunity was obtained after in vitro transformation of peripheral blood leukocytes from six positive patients. Furthermore, in vitro immortalization of B-lymphocytes unmasked existent ErbB2 immunity in 1 of 8 patients negative for ErbB2 serum antibodies. Determining shed ErbB2 extracellular domain as an indirect measure of tumor burden in ErbB2-positive malignancy, elevated serum levels were observed in 16 of 71 breast cancer and 1 of 31 normal donor sera Strikingly, existing ErbB2 immunity correlated significantly with elevated shed ErbB2 ectodomain among the patients analyzed. Incidence of both ErbB2 immunity and elevated ErbB2 extracellular domain increased with a progressed disease stage and was significantly associated with metastatic breast cancer. These observations implicate soluble ErbB2 amounts in vivo in the development of ErbB2 immunity in breast canter. They further project serum analysis of ErbB2 immunity and soluble ectodomain as potential markers of disease progression in ErbB2-positive malignancy.
2000
01 Pubblicazione su rivista::01a Articolo in rivista
ErbB2 immune response in breast cancer patients with soluble receptor ectodomain / Visco, Vincenzo; Roberto, Bei; Enrica, Moriconi; Gianni W., Kraus Mh; Raffaella, Muraro. - In: THE AMERICAN JOURNAL OF PATHOLOGY. - ISSN 0002-9440. - 156:4(2000), pp. 1417-1424. [10.1016/s0002-9440(10)65010-9]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/129027
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 21
social impact